BIOMARIN PHARMACEUTICAL INC
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the three months ended June 30, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.
Restructuring Plan
On April 27, 2026, we committed to a restructuring plan related to the integration of Amicus. This restructuring plan is intended to realize certain targeted synergies following the acquisition, primarily through reductions in overlapping personnel costs within the general and administrative functions. In connection with this restructuring plan, we expect to incur pre-tax charges of approximately $92.0 million representing one-time cash expenditures for severance and other employee termination benefits. These amounts represent an estimate which is subject to change as we finalize our assessment. Restructuring associated with severance actions are expected to be completed in phases through April 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.